Literature DB >> 28324302

Huntington's Disease-Update on Treatments.

Kara J Wyant1, Andrew J Ridder2, Praveen Dayalu2.   

Abstract

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, ending in death. Despite the discovery of the underlying genetic mutation more than 20 years ago, treatment remains focused on symptomatic management. Chorea, the most recognizable symptom, responds to medication that reduces dopaminergic neurotransmission. Psychiatric symptoms such as depression and anxiety may also respond well to symptomatic therapies. Unfortunately, many other symptoms do not respond to current treatments. Furthermore, high-quality evidence for treatment of HD in general remains limited. To date, there has been minimal success with identifying a disease-modifying therapy based upon molecular models. However, one of the emerging gene silencing techniques may provide a breakthrough in treating this devastating disease.

Entities:  

Keywords:  Behavioral; Chorea; Cognitive; Huntington; Neurodegeneration; Treatment

Mesh:

Year:  2017        PMID: 28324302     DOI: 10.1007/s11910-017-0739-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  123 in total

1.  Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Authors: 
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

2.  The long-term effect of tetrabenazine in the management of Huntington disease.

Authors:  Alfonso Fasano; Federica Cadeddu; Arianna Guidubaldi; Carla Piano; Francesco Soleti; Paola Zinzi; Anna Rita Bentivoglio
Journal:  Clin Neuropharmacol       Date:  2008 Nov-Dec       Impact factor: 1.592

3.  Tetrabenazine.

Authors:  Michael R Hayden; Blair R Leavitt; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

4.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.

Authors:  P G Como; A J Rubin; C F O'Brien; K Lawler; C Hickey; A E Rubin; R Henderson; M P McDermott; M McDermott; K Steinberg; I Shoulson
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

6.  Suicide risk in Huntington's disease.

Authors:  L Di Maio; F Squitieri; G Napolitano; G Campanella; J A Trofatter; P M Conneally
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

7.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Margaret E O'Rourke; Peg Nopoulos; Henry L Paulson; Jane S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2008 Jan-Mar       Impact factor: 1.567

8.  Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease.

Authors:  Frances M Velez-Lago; Amanda Thompson; Genko Oyama; Angela Hardwick; Justin M Sporrer; Pamela Zeilman; Kelly D Foote; Dawn Bowers; Herbert E Ward; Juan Sanchez-Ramos; Michael S Okun
Journal:  Stereotact Funct Neurosurg       Date:  2013-01-22       Impact factor: 1.875

9.  Ziprasidone in Huntington's disease: the first case reports.

Authors:  Raphael M Bonelli; Brigitte M Mayr; Gerald Niederwieser; Franz Reisecker; Hans-Peter Kapfhammer
Journal:  J Psychopharmacol       Date:  2003-12       Impact factor: 4.153

10.  Riluzole in Huntington's disease: a 3-year, randomized controlled study.

Authors:  G Bernhard Landwehrmeyer; Bruno Dubois; Justo Garcia de Yébenes; Berry Kremer; Wilhelm Gaus; Peter H Kraus; Horst Przuntek; Michel Dib; Adam Doble; Wilhelm Fischer; Albert C Ludolph
Journal:  Ann Neurol       Date:  2007-09       Impact factor: 10.422

View more
  34 in total

Review 1.  Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.

Authors:  Young-A Heo; Lesley J Scott
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 2.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

Review 3.  Inflammation in CNS neurodegenerative diseases.

Authors:  Jodie Stephenson; Erik Nutma; Paul van der Valk; Sandra Amor
Journal:  Immunology       Date:  2018-04-17       Impact factor: 7.397

Review 4.  Therapeutic Potential of Astrocyte Transplantation.

Authors:  Nataly Hastings; Wei-Li Kuan; Andrew Osborne; Mark R N Kotter
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

5.  deutetrabenazine for the treatment of chorea associated with Huntington's disease.

Authors:  Harshit Gupta; Wil Perkins; Cain Stark; Sathya Kikkeri; Juyeon Kakazu; Adam Kaye; Alan Kaye
Journal:  Health Psychol Res       Date:  2022-06-28

Review 6.  Mechanisms of Ferroptosis and Emerging Links to the Pathology of Neurodegenerative Diseases.

Authors:  Yiyan Sun; Xiaohuan Xia; Diksha Basnet; Jialin C Zheng; Jian Huang; Jianhui Liu
Journal:  Front Aging Neurosci       Date:  2022-06-28       Impact factor: 5.702

Review 7.  Spermatozoan Metabolism as a Non-Traditional Model for the Study of Huntington's Disease.

Authors:  Meghan Lawlor; Michal Zigo; Karl Kerns; In Ki Cho; Charles A Easley Iv; Peter Sutovsky
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 8.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

9.  Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.

Authors:  Jun Wu; Daniel Ryskamp; Lutz Birnbaumer; Ilya Bezprozvanny
Journal:  J Huntingtons Dis       Date:  2018

Review 10.  Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity.

Authors:  Annika Heinz; Deepti Kailash Nabariya; Sybille Krauss
Journal:  Toxins (Basel)       Date:  2021-07-14       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.